Smith+Nephew unveils digital platform to boost care
NEW YORK: Smith & Nephew plc SNN, also known as Smith+Nephew, recently launched ARIA, a digital platform and application developed to connect delivery of patient care with providers throughout the surgical and clinical episode. Notably, ARIA is fueled by the company’s Real Intelligence digital ecosystem and Positive Connections ASC solutions program.
This development is expected to boost the company’s Global Orthopaedics segment.
With the help of this platform, the company aims to help clinicians reduce the patient’s post-acute recovery time, develop efficiencies that cut down costs and deliver key Patient Reported Outcome Measures (PROMs) and satisfaction data to better define value for both patient and the site of care. The platform comprises customizable patient engagement pathways and facilitates connected, automated communication between the care navigator and patient. Additionally, ARIA exhibits dashboards that provide visibility for the patient and help lessen variability in clinical outcomes.
Apart from these, the platform ensures secure communication with referring providers and generates data that ambulatory surgery centers or clinical practices may utilize when communicating with payers.
ARIA will help customers leverage digital connectivity with patients and their referral network to break down traditional barriers, thereby improving patient compliance and reducing readmission risk utilizing objective data.
For investors’ notice, Smith+Nephew acquired two digital technology products — MiJourney and Rapid Recovery Pathways — in February 2020. The foundation for ARIA was designed on MiJourney, and Rapid Recovery Pathways will be integrated into the platform later this year.
In July 2020, the company announced the launch of the RI.HIP NAVIGATION for total hip arthroplasty (THA). This new technology has been developed to help maximize precision and reproducibility by delivering patient-specific component alignment — a crucial factor for surgeons in the evaluation of individual THA cases. This is also expected to boost the company’s Orthopaedic segment.
